Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지

The Comparion of Pregnancy Outcomes between GnRH Agonist and GnRH Antagonist Cycles in Women with Advanced Age

37세 이상의 환자에서 체외수정시술시 GnRH Agonist 주기와 GnRH Antagonist 주기의 비교 연구

  • Park, Chan Woo (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Cha, Sun Wha (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Hae Suk (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Hye Ok (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Yang, Kwang Moon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jin Young (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Song, In Ok (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Yoo, Keun Jae (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Kang, Inn Soo (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine) ;
  • Koong, Mi Kyoung (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Samsung Cheil Hospital and Women's Healthcare Center, Sungkyunkwan University School of Medicine)
  • 박찬우 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 차선화 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 김해숙 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 김혜옥 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 양광문 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 김진영 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 송인옥 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 유근재 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 강인수 (성균관대학교 의과대학 삼성제일병원 산부인과) ;
  • 궁미경 (성균관대학교 의과대학 삼성제일병원 산부인과)
  • Published : 2005.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To compare the clinical results and pregnancy outcomes of in vitro fertilization (IVF) between GnRH antagonist cycles and GnRH agonist (GnRH-a) cycles including flare-up and long protocol in women with advanced age. Materials and Methods: Retrospective clinical study. From January 2001 to September 2003, IVF cycles of female patient 37 years over were included in this study. GnRH-a long protocol (62 cycles, 61 patients) and GnRH antagonist multi-dose flexible protocol (66 cycles, 51 patients) were compared with the control group of GnRH-a flare-up protocol (151 cycles, 138 patients). IVF cycles for non-obstructive azoospermia (NOA), endometriosis III, IV and polycystic ovarian syndrome (PCOS) were excluded in this study. Clinical results such as total gonadotropin dose, serum E2 on hCG administration, the number of retrieved oocytes and the pregnancy outcomes - clinical pregnancy rate (CPR), implantation rate (IR) and live birth rate (LBR) per embryo transfer - were compared. Results: There were significant differences in the total dose of gonadotropin (GnRH-a flare-up vs. GnRH-a long vs. GnRH-antagonist; 41.8 vs. 54.7 vs. 24.8), serum E2 on hCG administration (1787.2 vs. 1881.6 vs. 788.0), the numbers of retrieved oocytes (8.1 vs. 11.1 vs. 4.5) and endometrial thickness (9.1 vs. 10.4 vs. 8.0) which were significantly lower in GnRH-antagonist cycles. But pregnancy outcomes shows no significant differenced in CPR (25.0% vs. 35.8% vs. 24.5%), IR (11.7% vs. 12.3% vs. 10.1%) and LBR (15.8% vs. 28.3% vs. 15.1%) Conclusion: In women with advanced age, GnRH-antagonist cycles can result in comparable pregnancy outcomes to GnRH-a cycles including flare-up and long protocol. GnRH-a long protocol show higher CPR, IR and LBR than GnRH antagonist multi-dose flexible protocol and flare-up protocol without significant differences.

Keywords

References

  1. Feldberg D, Farhi J, Ashkenazi J, Dicker D, Shalev J, Ben Rafael Z. Minidose gonadotropin releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil Steril 1994; 62: 343-6
  2. Garcia-Velasco JA, Isaza V, Requena A, MartfnezSalazar F, Landazabal A, Remohf J, et al. High doses of gonadotrophins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: a prospective, randomized, controlled trial. Hum Reprod 2000; 15: 2292-6 https://doi.org/10.1093/humrep/15.11.2292
  3. Garcia J, Padilla S, Bargati J, Baramki T. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for in vitro fertilization. Fertil Steril 1990; 53: 302-5
  4. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994; 61: 880-5
  5. 박찬우, 궁미경, 양광문, 김진영, 유근재, 서주태 등. 폐쇄성 무정자증과 비폐쇄성 정자증에서 체외수정시술의 후의 임신 결과 비교. 대한불임회지 2003;30:207-15
  6. Barnhart K, Dunsrnoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril 2002; 77: 1148-55 https://doi.org/10.1016/S0015-0282(02)03112-6
  7. Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE, et al. Incidence of early loss of pregn.ancy. N Engl J Med 1988; 319: 189-94 https://doi.org/10.1056/NEJM198807283190401
  8. Stirrat GM. Recurrent miscarriage. Lancet 1990; 336: 673-5 https://doi.org/10.1016/0140-6736(90)92159-F
  9. Muasher SJ. Controversies in assisted reproduction: treatment of low responders. J Assist Reprod Genetics 1993; 10: 112-4 https://doi.org/10.1007/BF01207730
  10. Navot D, Drews MR, Bergh PA, Guzman I, Karstaedt A, Scott RT, et al. Age-related decline in female fertility is not due to diminished capacity of the uterus to sustain embryo implantation. Fertil Steril 1994; 61: 97-101
  11. Tasdemir M, Tasdemir I, Kodama H, Fukuda J, Tanaka T. Short protocol of gonadotropin releasing hormone agonist administration gave better results in long protocol poor-responders in lVF-ET. Obstet Gynaecol 1996; 22: 73-7
  12. Toth T, Awwad J, Veeck L, Jones H, Muasher S. Suppression and flare regimens of gonadotropinreleasing hormone agonist: use in women with different basal gonadotropin values in an in vitro fertilization program. J Reprod Med 1996; 41: 321-6
  13. Katayama K, Roesler M, Gunnarson G, Stehlik E, Jagusch S. Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization. J In Vitro Fert Embryo Transfer 1988; 5: 332-7 https://doi.org/10.1007/BF01129568
  14. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-upprotocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001; 16: 868-70 https://doi.org/10.1093/humrep/16.5.868
  15. Fasouliotis Sl, Laufer N, Sabbagh-Ehrlich S, Lewin A, Hurwitz A, Simon A. Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVE. J Assist Reprod Genet 2003; 20: 455-60 https://doi.org/10.1023/B:JARG.0000006707.88826.e7
  16. Mohamed KA, Davies WA, Allsopp J, Lashen H. Agonist 'flare-up' versus antagonist in the management of poor responders undergoing in vitro fertilization treatment. Fertil Steril 2005; 83: 331-5 https://doi.org/10.1016/j.fertnstert.2004.07.963
  17. Nikolettos N, Al-Hasani S, Felberbaum R, Demirel LC, Kupker W, Montzka P, et al. Gonadotropinreleasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 2001; 97: 202-7 https://doi.org/10.1016/S0301-2115(00)00535-2
  18. Dekel N, Lewysohn O, Ayalon D, Hazum E. Receptor for GnRH are present in rat oocytes. Endocrinology 1988; 123: 1205-7 https://doi.org/10.1210/endo-123-2-1205
  19. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT Jr, LeRoith D, et al. Luteinizing hormonereleasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 1993; 77: 963-8 https://doi.org/10.1210/jc.77.4.963
  20. Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, LeRoith D, et al. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased IGF-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 1996; 137: 1089-95 https://doi.org/10.1210/en.137.3.1089
  21. Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L, et al. GnRH receptors in human granulosa cells: anatornicallocalization and characterization by autoradiographic study. Endocrinology 1989; 125: 1739-41 https://doi.org/10.1210/endo-125-3-1739
  22. Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa lutein cells. Am J Obstet Gynecol 1995a; 172: 1518-25 https://doi.org/10.1016/0002-9378(95)90490-5
  23. Lin Y,Kahn JA, Hillensjo T. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophinreleasing hormone antagonist? Hum Reprod 1999; 14: 885-8 https://doi.org/10.1093/humrep/14.4.885
  24. Ortmann O, Oltmanns K, Weiss JM, et al. Effects of the GnRH antagonist Cetrorelix on steroidogenesis in human granulosa lutein cells. Hum Reprod 1998; 13(Abstract Book), P-252
  25. Hermann R, Scheider E, Romeis P. Pharmacokinetics and pharmacodynamics of the LH-RH-antagonist Cetrorelix in healthy male and female subjects. Gynecol Endocrinol 1996; 10 (suppl. 1): 9-15 https://doi.org/10.3109/09513599609045619